Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials

Schizophrenia Research

Volumn 140, Issue 1-3, 2012, Pages 159-168

  Caemmerer, Jacqueline ^a   Correll, Christoph U ^b,c,d,e   Maayan, Lawrence ^a,f  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Antipsychotics; Behavioral; CBT; Diet; Exercise; Healthy lifestyle; Intervention; Metabolic syndrome; Nutritional interventions; Treatment; Weight gain

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CLOZAPINE; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; COGNITIVE THERAPY; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EDUCATION PROGRAM; FEMALE; HUMAN; KINESIOTHERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METABOLIC DISORDER; MOOD DISORDER; NUTRITIONAL COUNSELING; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; OUTPATIENT CARE; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BEHAVIOR THERAPY; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; METABOLIC DISEASES; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84865335577     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.03.017     Document Type: Article

References (44)

1. Allison D.B., Mentore J.L., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999, 156(11):1686-1696.
2. Allison D.B., Mackell J.A., McDonnell D.D. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr. Serv. 2003, 54(4):565-567.
3. Alvarez-Jimenez M., Gonzalez-Blanch C., Vazquez-Barquero J.L., Perez-Iglesias R., Martinez-Garcia O., Perez-Pardal T., Ramirez-Bonilla M.L., Crespo-Facorro B. Attenuation of antipsychotic-inducted weight gain with early behavioral intervention in drug-naïve first-episode psychosis patients: a randomized controlled trial. J. Clin. Psychiatry 2006, 67:1253-1260.
4. Alvarez-Jimenez M., Hetrick S.E., Gonzalez-Blanch C., Gleeson J.F., McGorry P.D. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br. J. Psychiatry 2008, 193:101-107.
5. Alvarez-Jimenez M., Martinez-Garcia O., Perez-Iglesias R., Ramirez M.L., Vazquez-Barquero J.L., Crespo-Facorro B. Prevention of antipsychotic-induced weight gain with early behavioral intervention in first episode psychosis: 2-year results if a randomized controlled trial. Schizophr. Res. 2010, 116:16-19.
6. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry 2004, 65(2):267-272.
7. Beebe L.H., Tian L., Morris N., Goodwin A., Allen S.S., Kuldau J. Effects of exercise on mental and physical health parameters of persons with schizophrenia. Issues Ment. Health Nurs. 2005, 26:661-676.
8. Brar J.S., Ganguli R., Pandina G., Turkoz I., Berry S., Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 2005, 66:205-212.
9. Cordes, J., Thunker, J., Regenbrecht, J.Z., Correll, C.U., Schmidt-Kraepelin, C., Lange-Asschenfeldt, C., Agelink, M.W., Kahl, K.G., Gaebel, W., Klimke, A., Hauner, H., in press. Can an early weight management program (WMP) prevent olanzapine-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four and 48-week results from a 6-month randomized trial. World J. Biol. Psychiatry.
10. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhotra A.K. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302(16):1765-1773.
11. Correll C.U., Sheridan E.M., DelBello M.P. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010, 12(2):116-141.
12. Correll C.U., Kratochvil C.J., March J. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants and antipsychotics. J. Clin. Psychiatry 2011, 72(5):655-670.
13. Correll C.U., Lencz T., Malhotra A.K. Antipsychotic drugs and obesity. Trends Mol. Med. 2011, 17(2):97-107.
14. De Hert M., Correll C.U., Bobes J., Cetkovich-Bakmas M., Cohen D., Asai I., Detraux J., Gautam S., Möller H.J., Ndetei D.M., Newcomer J.M., Uwakwe R., Leucht S. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011, 10(1):52-77.
15. De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2012, 8(2):114-126.
16. Evans S., Newton R., Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust. N. Z. J. Psychiatry 2005, 39:479-486.
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285(19):2486-2497.
18. Gabriele J.M., Dubbert P.M., Reeves R.R. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. Obes. Rev. 2009, 10:442-455.
19. Haffner S.M. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity 2006, 14:121-127.
20. Kahn R.S., Fleischhacker W.W., Boter H., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371(9618):1085-1097.
21. Khazaal Y., Fresard E., Rabia S., Chatton A., Rothen S., Pomini V., Grasset F., Borgeat F., Zullino D. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr. Res. 2007, 169-177.
22. Kwon J.S., Choi J.S., Bahk W.M., Kim C.Y., Kim C.H., Shin Y.C., Park B.J., Oh C.G. Weight management program from treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J. Clin. Psychiatry 2006, 67:547-553.
23. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009, 14(4):429-447.
24. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
25. Littrell K.H., Hilligoss N.M., Kirshner C.D., Petty R.G., Johnson C.G. The effects of an educational intervention on antipsychotic-induced weight gain. J. Nurs. Scholarsh. 2003, 3(23):7-241.
26. Maayan L., Correll C.U. Management of antipsychotic-related weight gain. Expert. Rev. Neurother. 2010, 10:175-1200.
27. Maayan L., Correll C.U. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J. Child Adolesc. Psychopharmacol. 2011, 21(6):517-535.
28. Maayan L., Vakhrusheva J., Correll C.U. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010, 35:1520-1530.
29. Maher A.R., Maglione M., Bagley S., Suttorp M., Hu J.H., Ewing B., Wang Z., Timmer M., Sultzer D., Shekelle P.G. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011, 306(12):1359-1369.
30. Mauri M., Simnocini M., Castrogiovianni S., Iovieno N., Dell'Agnello G., Quadrigli M., Rossi A., Donda P., Fagiolini A., Cassano G.B. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry 2008, 41:17-23.
31. McKibbin C.L., Patterson T.L., Norman G., Patrick K., Jin H., Roesch S., Mudaliar S., Barrio C., O'Hanlon K., Griver K., Sirkin A., Jeste D.V. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr. Res. 2006, 86:36-44.
32. Melamed Y., Stein-Reisner O., Gelkopf M., Levi G., Sivan T., Ilievici G., Rosenberg R., Weizman A., Bleich A. Multi-modal weight control intervention for people with persistent mental disorders. Psychiatr. Rehabil. J. 2008, 31:194-200.
33. Mukundan A., Faulkner G., Cohn T., Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst. Rev. 2010, (12):CD006629.
34. Narula P.K., Rehan H.S., Unni K.E., Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr. Res. 2010, 118(1-3):218-223.
35. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 2009, 166(9):980-991.
36. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl. 1):1-93.
37. Poulin M.J., Chaput J.P., Simard V., Vicent P., Bernier J., Gauthier Y., Lanctot G., Saindon J., Vincent A., Gagnon S., Tremblay A. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust. N. Z. J. Psychiatry 2007, 41:980-989.
38. Scocco P., Longo R., Caon F. Weight change in treatment with olanzapine and a psychoeducational approach. Eat. Behav. 2006, 7:115-124.
39. Skrinar G.S., Huxley N.A., Hutchinson D.S., Menninger E., Glew P. The role of a fitness intervention on people with serious psychiatric disabilities. Psychiatr. Rehabil. J. 2005, 29:122-127.
40. Stroup T.S., McEvoy J.P., Ring K.D., Hamer R.H., LaVange L.M., Swartz M.S., Rosenheck R.A., Perkins D.O., Nussbaum A.M., Lieberman J.A., Schizophrenia Trials Network A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am. J. Psychiatry 2011, 168(9):947-956.
41. Weber M., Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr. Res. 2006, 83:95-101.
42. Wu M.K., Wang C.K., Bai Y.M., Huang C.Y., Lee S.D. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr. Serv. 2007, 58:544-550.
43. Wu R.R., Zhao J.P., Jin H., Fang M.S., Guo X.F., et al. Lifestyle intervention and metformin for treatment of anti-psychotic induced weight gain: a randomized controlled trial. JAMA 2008, 185-193.
44. Zhang J.P., Weiss J., McCardle M., Kofman M., Rosendahl E., Maayan L., Convit A., Manu P., Kane J.M., Correll C.U. Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with non-psychotic disorders or no psychiatric disorders: Results from a 12-month, real-world study. J. Clin. Psychopharmacol. 2012, 32:458-464.